Avalo Therapeutics, Inc. (AVTX)
14.41
-1.51
(-9.48%)
USD |
NASDAQ |
Apr 08, 16:00
14.41
0.00 (0.00%)
Pre-Market: 08:47
Avalo Therapeutics Shareholders Equity (Quarterly) : 83.05M for Dec. 31, 2025
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| AbbVie, Inc. | -3.27B |
| Corcept Therapeutics, Inc. | 647.80M |
| Catalyst Pharmaceuticals, Inc. | 954.27M |
| Relmada Therapeutics, Inc. | 86.51M |
| Theravance Biopharma, Inc. | 296.72M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 117.70M |
| Total Liabilities (Quarterly) | 34.65M |
| Debt to Equity Ratio | 0.0292 |
| Current Ratio | 8.136 |
| Net Debt Paydown Yield | -0.05% |